Form 4: UTHR CEO Rothblatt Executes Planned Stock Option Exercise, Sales

United Therapeutics CEO Martine Rothblatt exercised stock options and sold shares as part of a pre-arranged 10b5-1 trading plan.

Summary

• Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp (UTHR), exercised 9,500 stock options on March 17, 2026, at an exercise price of $146.03 per share.
• Concurrently, Rothblatt sold 9,500 shares of common stock in multiple transactions on March 17, 2026, at weighted average prices ranging from $531.2113 to $540.92 per share.
• These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025.
• Following these transactions, Rothblatt directly holds 40,513 shares of common stock and indirectly holds 381,197 shares through various family trusts and a spouse.
• Rothblatt also directly holds 126,000 unexercised stock options.
• The 10b5-1 plan is set to continue until the earlier of the exercise of 1,734,410 stock options (expiring March 17, 2027) or December 31, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. The transactions are routine insider sales executed under a pre-arranged 10b5-1 plan, which is a common practice for executives managing their equity compensation.

Positives

• The transactions were conducted under a pre-arranged Rule 10b5-1 trading plan, indicating a systematic and pre-scheduled approach to managing equity holdings rather than a reaction to immediate market conditions.
• The CEO continues to hold a significant number of shares directly and indirectly, demonstrating ongoing alignment with shareholder interests.
• The exercise of options at $146.03 and sale at prices over $530 indicates a substantial gain for the reporting person.

Negatives

• The direct beneficial ownership of common stock decreased by 9,500 shares as a result of the sales.

Future Outlook

The pre-arranged 10b5-1 trading plan is scheduled to continue until the earlier of the exercise of 1,734,410 stock options (which expire on March 17, 2027) or December 31, 2026, indicating further planned transactions by the reporting person.

Industry Context

StockSavvy.ai notes that insider transactions, particularly those executed under Rule 10b5-1 plans, are common practice for executives to manage their equity compensation and personal finances in a compliant manner. These routine sales typically do not reflect a change in the company's fundamental outlook or the executive's confidence in the business, especially in the biotechnology and pharmaceutical sectors where executive compensation often includes substantial equity components.

Related Party Transactions

• Indirect beneficial ownership includes shares held by a spouse and various family trusts where the reporting person or immediate family members are beneficiaries or have shared investment power.

Stakeholder Impact

• Shareholders: The sale of shares by a key executive could be perceived negatively by some, but the pre-arranged nature of the 10b5-1 plan mitigates concerns about opportunistic selling. The executive retains significant direct and indirect holdings.
• Employees: No direct impact mentioned.
• Customers: No direct impact mentioned.
• Suppliers: No direct impact mentioned.
• Creditors: No direct impact mentioned.

Next Steps

• The 10b5-1 trading plan will continue, with further exercises and sales of up to 1,734,410 stock options planned until December 31, 2026, or until all options expiring March 17, 2027, are exercised.

Key Dates

Recommendation

The filing details a routine insider transaction (option exercise and sale) executed under a pre-arranged 10b5-1 plan. This type of transaction is generally not indicative of a change in the company's fundamentals or the executive's long-term outlook, and therefore, does not warrant a change in investment recommendation based solely on this filing. The executive maintains substantial direct and indirect holdings.

Keywords

United Therapeutics, UTHR, Martine Rothblatt, Insider Trading, Form 4, Stock Options, 10b5-1 Plan, CEO, Biotechnology, Pharmaceuticals